Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase.
Human African trypanosomiasis, caused by the eukaryotic parasite Trypanosoma brucei, is a serious health problem in much of central Africa. The only validated molecular target for treatment of human African trypanosomiasis is ornithine decarboxylase (ODC), which catalyzes the first step in polyamine metabolism. Here, we describe the use of an enzymatic high throughput screen of 316,114 unique molecules to identify potent and selective inhibitors of ODC. This screen identified four novel families of ODC inhibitors, including the first inhibitors selective for the parasitic enzyme. These compounds display unique binding modes, suggesting the presence of allosteric regulatory sites on the enzyme. Docking of a subset of these inhibitors, coupled with mutagenesis, also supports the existence of these allosteric sites.
Smithson
David C
DC
Department of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Lee
Jeongmi
J
Shelat
Anang A
AA
Phillips
Margaret A
MA
Guy
R Kiplin
RK
D000495:Allosteric Site; D000818:Animals; D001331:Automation; D002626:Chemistry, Pharmaceutical / Q000379:methods; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology*; D006801:Humans; D008291:Malate Dehydrogenase / Q000737:chemistry; D016297:Mutagenesis, Site-Directed; D065108:Ornithine Decarboxylase Inhibitors; D010730:Phosphoenolpyruvate Carboxylase / Q000737:chemistry; D011485:Protein Binding; D014344:Trypanocidal Agents / Q000494:pharmacology; D014346:Trypanosoma brucei brucei / Q000201:enzymology*; D014353:Trypanosomiasis, African / Q000188:drug therapy
D004791:Enzyme Inhibitors; D065108:Ornithine Decarboxylase Inhibitors; D014344:Trypanocidal Agents; D008291:Malate Dehydrogenase; D010730:Phosphoenolpyruvate Carboxylase